

# Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/T9D1EBC89BB2EN.html>

Date: March 2022

Pages: 121

Price: US\$ 3,500.00 (Single User License)

ID: T9D1EBC89BB2EN

## Abstracts

Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

According to the recently published report 'Toll Like Receptor 8 - Drugs In Development, 2022'; Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 35 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes.

Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It controls host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.

The report 'Toll Like Receptor 8 - Drugs In Development, 2022' outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 11, 7, 12 and 3 respectively. Similarly, the

universities portfolio in Discovery stages comprises 1 molecule, respectively.

Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Solid Tumor, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Hepatitis B, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), Bladder Cancer, Gastric Cancer, Autoimmune Disorders, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Cervical Cancer, Cutaneous Lupus Erythematosus, Fibrosis, Gastroesophageal (GE) Junction Carcinomas, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2<sup>-</sup> Breast Cancer), Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2<sup>+</sup> Breast Cancer), Merkel Cell Carcinoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Nasopharyngeal Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Prostate Cancer, Renal Cell Carcinoma, Sarcomas, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer), Unspecified Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Anal Cancer, Arthritis, Chondrosarcoma, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Colon Cancer, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Pneumonia, Cutaneous T-Cell Lymphoma, Endometrial Cancer, Esophageal Cancer, Ewing Sarcoma, Head And Neck Cancer, Hepatocellular Carcinoma, Hypopharyngeal Cancer, Inflammation, Kaposi Sarcoma, Laryngeal Cancer, Leiomyosarcoma, Leukemia, Medullary Thyroid Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Mycosis Fungoides, Neuroendocrine Tumors, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteoarthritis, Osteosarcoma, Pancreatic Cancer, Penile Cancer, Pleomorphic Liposarcoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Subacute Cutaneous Lupus Erythematosus (SCLE), Synovial Sarcoma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)

The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects

The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Toll Like Receptor 8 (CD288 or TLR8) - Overview

Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics  
Development

Altimune Inc

Ambrx Biopharma Inc

Ascendis Pharma AS

Avidea Technologies Inc

Bolt Biotherapeutics Inc

Bristol-Myers Squibb Co

Curebiotech Inc

Curevac NV

Dynavax Technologies Corp

Eisai Co Ltd

Galderma SA

Gilead Sciences Inc

IngenoVax LLC

Janus Biotherapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

Merck KGaA

Nektar Therapeutics

Novartis AG

Resolve Therapeutics LLC

Seven and Eight Biopharmaceuticals Corp

Seven and Eight Biopharmaceuticals Inc

Shanghai De Novo Pharmatech Co Ltd

Shanghai Zhimeng Biopharma Inc  
Silverback Therapeutics Inc  
UroGen Pharma Ltd  
Vaccex Inc  
Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles  
afimetonan - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
ALT-702 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
BDB-001 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
BDB-018 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
BDB-030 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
BDB-102 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
BDC-1001 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
CB06-036 - Drug Profile  
Product Description  
Mechanism Of Action  
CUCPT-8m - Drug Profile  
Product Description  
Mechanism Of Action  
CV-8102 - Drug Profile  
Product Description

Mechanism Of Action

History of Events

DN-1508052 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs to Agonize TLR8 for Fibrosis and Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

E-6742 - Drug Profile

Product Description

Mechanism Of Action

History of Events

enpatoran - Drug Profile

Product Description

Mechanism Of Action

History of Events

HRS-9950 - Drug Profile

Product Description

Mechanism Of Action

imiquimod - Drug Profile

Product Description

Mechanism Of Action

History of Events

imiquimod + zalifrelimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

INGMM-1 - Drug Profile

Product Description

Mechanism Of Action

JB-6121 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibody Conjugates to Agonize TLR 7 and 8 for Unspecified Cancer - Drug Profile

Product Description

Mechanism Of Action

motolimod - Drug Profile

Product Description

Mechanism Of Action

History of Events

NKTR-262 - Drug Profile

Product Description

Mechanism Of Action

History of Events

resiquimod - Drug Profile

Product Description

Mechanism Of Action

History of Events

resiquimod - Drug Profile

Product Description

Mechanism Of Action

History of Events

resiquimod SR - Drug Profile

Product Description

Mechanism Of Action

History of Events

RSLV-132 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SBT-6050 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SBT-6290 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SBT-8230 - Drug Profile

Product Description

Mechanism Of Action

History of Events

selgantolimod - Drug Profile

Product Description

Mechanism Of Action



History of Events

Small Molecule to Agonize TLR7 and TLR8 for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Antagonize TLR7 and TLR8 for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Antagonize TLR8 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

History of Events

SYN-001 - Drug Profile

Product Description

Mechanism Of Action

VTX-1463 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products

Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones

Featured News & Press Releases

Jan 06, 2022: Bolt Biotherapeutics doses first patient with BDC-1001 in combination with OPDIVO (nivolumab) in ongoing phase 1/2 clinical trial for the Treatment of HER2-expressing solid tumors

Dec 14, 2021: Ascendis Pharma virtual R&D program update highlights continued development across R&D pipeline

Dec 07, 2021: Ascendis Pharma to host virtual R&D program update on December

Dec 06, 2021: Bolt Biotherapeutics reports interim BDC-1001 phase 1/2 data demonstrating a safe and well-tolerated profile and emerging clinical activity at the ESMO Immuno-Oncology Congress 2021

Dec 02, 2021: Bolt Biotherapeutics to present interim clinical data on BDC-1001 phase 1/2 clinical trial at ESMO Immuno-Oncology Congress 2021

Nov 13, 2021: Seven and Eight Biopharma's BDB001 in combination with an anti-PD-L1 mAb shows favorable safety and clinical responses in interim phase 1 data presented at the 2021 SITC Annual Meeting

Nov 12, 2021: Silverback Therapeutics presents preclinical data for SBT8230 at AASLD

## The Liver Meeting 2021

Nov 12, 2021: Silverback Therapeutics presents SBT6050-201 trial in progress poster at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

Nov 10, 2021: CureVac presents promising data at SITC from Phase 1 study of oncology candidate CV8102 showing systemic immune response

Nov 09, 2021: Ascendis Pharma presents new non-clinical data for TransCon TLR7/8 agonist oncology program at SITC 2021

Sep 16, 2021: Silverback Therapeutics presents interim clinical results from the ongoing phase 1/1b study of SBT6050 alone or in combination with Pembrolizumab in patients with advanced or metastatic HER2-expressing solid tumors

Sep 13, 2021: Silverback Therapeutics to present data from its phase 1/1b clinical trial of SBT6050 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress

Sep 07, 2021: Seven and Eight Biopharmaceuticals announces the first patient treated in a phase 2 clinical trial of the TLR 7/8 dual agonist BDB001 in anti-PD-1 / anti-PD-L1 refractory solid tumors

Jun 24, 2021: Resolve Therapeutics to start Phase II Trial of RSLV-132 for long Covid

Jun 23, 2021: Seven and Eight Biopharmaceuticals announces the first patient treated in a first-in-human clinical trial of the TLR7/8 dual agonist BDB018 in advanced solid tumors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Indications, 2022 (Contd..3)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Companies, 2022 (Contd..6)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Altimune Inc, 2022

Pipeline by Ambrx Biopharma Inc, 2022

Pipeline by Ascendis Pharma AS, 2022

Pipeline by Avidia Technologies Inc, 2022

Pipeline by Bolt Biotherapeutics Inc, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Curebiotech Inc, 2022

Pipeline by Curevac NV, 2022

Pipeline by Dynavax Technologies Corp, 2022

Pipeline by Eisai Co Ltd, 2022

Pipeline by Galderma SA, 2022

Pipeline by Gilead Sciences Inc, 2022

Pipeline by IngenoVax LLC, 2022

Pipeline by Janus Biotherapeutics Inc, 2022

Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Pipeline by Merck KGaA, 2022

Pipeline by Nektar Therapeutics, 2022  
Pipeline by Novartis AG, 2022  
Pipeline by Resolve Therapeutics LLC, 2022  
Pipeline by Seven and Eight Biopharmaceuticals Corp, 2022  
Pipeline by Seven and Eight Biopharmaceuticals Inc, 2022  
Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022  
Pipeline by Shanghai Zhimeng Biopharma Inc, 2022  
Pipeline by Silverback Therapeutics Inc, 2022  
Pipeline by UroGen Pharma Ltd, 2022  
Pipeline by Vaccex Inc, 2022  
Dormant Products, 2022  
Dormant Products, 2022 (Contd..1)  
Dormant Products, 2022 (Contd..2)  
Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

## I would like to order

Product name: Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/T9D1EBC89BB2EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T9D1EBC89BB2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

